Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference Jan 07, 2021 4:02pm EST
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates Nov 05, 2020 4:01pm EST
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020 Nov 05, 2020 8:46am EST
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis Oct 23, 2020 7:00am EDT
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences Oct 15, 2020 7:00am EDT
Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology Sep 17, 2020 4:01pm EDT
Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology Sep 10, 2020 7:00am EDT
